Literature DB >> 12754353

Systemic infection, interleukin 1beta, and cognitive decline in Alzheimer's disease.

C Holmes1, M El-Okl, A L Williams, C Cunningham, D Wilcockson, V H Perry.   

Abstract

Activated microglia, the resident macrophages of the brain, are a feature of Alzheimer's disease. Animal models suggest that when activated microglia are further activated by a subsequent systemic infection this results in significantly raised levels of interleukin 1beta within the CNS, which may in turn potentiate neurodegeneration. This prospective pilot study in Alzheimer's disease subjects showed that cognitive function can be impaired for at least two months after the resolution of a systemic infection and that cognitive impairment is preceded by raised serum levels of interleukin 1beta. These relations were not confounded by the presence of any subsequent systemic infection or by baseline cognitive scores. Further research is needed to determine whether recurrent systemic infections drive cognitive decline in Alzheimer's disease subjects through a cytokine mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754353      PMCID: PMC1738504          DOI: 10.1136/jnnp.74.6.788

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  113 in total

1.  Amelioration of age associated neuroinflammation on long term bacosides treatment.

Authors:  Manisha Rastogi; Rudra P Ojha; B Parimala Devi; Aabha Aggarwal; Aruna Agrawal; G P Dubey
Journal:  Neurochem Res       Date:  2011-12-25       Impact factor: 3.996

2.  The impact of glial activation in the aging brain.

Authors:  Aileen M Lynch; Kevin J Murphy; Brian F Deighan; Julie-Ann O'Reilly; Yuri K Gun'ko; Thelma R Cowley; Rodrigo E Gonzalez-Reyes; Marina A Lynch
Journal:  Aging Dis       Date:  2010-09-04       Impact factor: 6.745

3.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

Review 4.  Heterogeneity of CNS myeloid cells and their roles in neurodegeneration.

Authors:  Marco Prinz; Josef Priller; Sangram S Sisodia; Richard M Ransohoff
Journal:  Nat Neurosci       Date:  2011-09-27       Impact factor: 24.884

5.  Antiviral agents in Alzheimer's disease: hope for the future?

Authors:  Matthew A Wozniak; Ruth F Itzhaki
Journal:  Ther Adv Neurol Disord       Date:  2010-05       Impact factor: 6.570

6.  Little exercise, big effects: reversing aging and infection-induced memory deficits, and underlying processes.

Authors:  Ruth M Barrientos; Matthew G Frank; Nicole Y Crysdale; Timothy R Chapman; Jared T Ahrendsen; Heidi E W Day; Serge Campeau; Linda R Watkins; Susan L Patterson; Steven F Maier
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

7.  A plea for the elective inclusion of the brain in routine whole-body FDG PET.

Authors:  Tarik Belhocine; Stefan Markus Weiner; Ingo Brink; Peter Paul De Deyn; Jan Roland; Thierry Van der Borght; Patrick Flamen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03       Impact factor: 9.236

Review 8.  Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Authors:  Tony Wyss-Coray; Joseph Rogers
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

9.  Proinflammatory cytokines, sickness behavior, and Alzheimer disease.

Authors:  C Holmes; C Cunningham; E Zotova; D Culliford; V H Perry
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 10.  Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment.

Authors:  Clive Holmes; Darren Cotterell
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.